Acetyl Gastric Inhibitory Peptide (human) (TFA)
(Synonyms: Human N-acetyl GIP TFA) 目录号 : GC68604Acetyl Gastric Inhibitory Peptide (human) (TFA)是一种合成的、化学修饰的人类抑胃肽。
Cas No.:299898-52-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Acetyl Gastric Inhibitory Peptide (human) (TFA) is a synthetic, chemically modified human gastric inhibitory peptide [1]. Acetyl Gastric Inhibitory Peptide (human) (TFA) is a physiological incretin hormone that can effectively stimulate insulin release in a glucose-dependent manner [2]. Acetyl Gastric Inhibitory Peptide (human) (TFA) is commonly used in metabolic disease research and diabetes drug development [3-4].
In adult male wistar rats, Acetyl Gastric Inhibitory Peptide (human) (TFA) (25nM/kg; ip; single injection) significantly reduces plasma glucose concentration [5].
References:
[1]. Flatt PR, O'harte FP, Utech Ltd. Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function. United States patent application US 11/991,638. 2009 Nov 19.
[2]. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009 Sep; 52: 1724-1731.
[3]. Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020 Mar; 125: 170202.
[4]. O'Harte F, Gault V, Parker J, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep; 45: 1281-1291.
[5]. Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biological chemistry. 2008 Feb; 389(2): 189-193.
Acetyl Gastric Inhibitory Peptide (human) (TFA)是一种合成的、化学修饰的人类抑胃肽 [1]。Acetyl Gastric Inhibitory Peptide (human) (TFA)是一种生理性肠促胰岛素激素，能够以葡萄糖依赖性方式有效刺激胰岛素释放 [2]。Acetyl Gastric Inhibitory Peptide (human) (TFA)常用于代谢疾病研究和糖尿病药物研发 [3-4]。
在成年雄性Wistar大鼠中，Acetyl Gastric Inhibitory Peptide (human) (TFA)（25nM/kg；腹腔注射；单次注射）显著降低血浆葡萄糖浓度 [5]。
| Animal experiment [1]: | |
Animal models | Adult male wistar rats |
Preparation Method | Plasma glucose and serum glucagon responses were evaluated following intraperitoneal injection of either saline (0.9%, w/v, NaCl) or glucose [18 mmol/kg body weight (b.w.)] alone or in combination with native Gastric Inhibitory Peptide (GIP), GLP-1, Acetyl Gastric Inhibitory Peptide (human) (TFA), GIP(Lys37)PAL, N-AcGIP(Lys37)PAL, (Pro3)GIP or (Pro3)GIP plus GIP (all at 25nM/kg b.w.). |
Dosage form | 25nM/kg; ip; single injection |
Applications | Acetyl Gastric Inhibitory Peptide (human) (TFA) significantly reduces plasma glucose concentration. |
References: | |
| Cas No. | 299898-52-5 | SDF | Download SDF |
| 别名 | Human N-acetyl GIP TFA | ||
| 分子式 | C228H340N60O67S.C2HF3O2 | 分子量 | 5139.62 |
| 溶解度 | H2O : 50 mg/mL (9.73 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.1946 mL | 0.9728 mL | 1.9457 mL |
| 5 mM | 0.0389 mL | 0.1946 mL | 0.3891 mL |
| 10 mM | 0.0195 mL | 0.0973 mL | 0.1946 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet